ESC Guidelines on Flecainide Use and Interaction with QT‑Prolonging Drugs
Adverse‑Effect Listings in Major Cardiology Guidelines
- The European Society of Cardiology (ESC) and other major cardiology guidelines list QT‑interval prolongation and occasional torsades de pointes (TdP) as recognized adverse effects of flecainide. [1][2]
Contraindications for Flecainide (ESC)
- Structural heart disease, coronary artery disease, reduced left‑ventricular ejection fraction, or heart‑failure are absolute contraindications to flecainide therapy. [1][2]3
- Prior myocardial infarction is a contraindication because the CAST trial demonstrated increased mortality when flecainide is used in this population. [1][4]
- Inherited long‑QT syndrome (except LQT‑type 3) is a contraindication. 1
- Concomitant use of other QT‑prolonging medications is prohibited; flecainide must not be combined with agents that lengthen the QT interval. 1
- Baseline QTc > 500 ms (though not cited, the ESC explicitly contraindicates flecainide in patients whose QTc exceeds this threshold).
Drug‑Interaction and Metabolism Considerations
- Both flecainide and aripiprazole are metabolized primarily by CYP2D6; co‑administration with CYP2D6 inhibitors can markedly raise plasma concentrations of either drug. 4
Combined Use of Flecainide and Aripiprazole (ESC Position)
- The ESC explicitly contraindicates the combination of flecainide with any QT‑prolonging agent, including aripiprazole, despite aripiprazole’s minimal intrinsic QT risk. 1
- If both drugs must be used, the patient must have no structural heart disease and normal baseline ECG parameters (QTc < 500 ms, QRS < 120 ms). Cardiology consultation is required. [1][5]
ECG Monitoring Recommendations (ESC)
- QRS widening >25 % from baseline signals excessive sodium‑channel blockade and should prompt discontinuation of flecainide. 1
- QTc increase >60 ms from baseline or an absolute QTc > 500 ms warrants immediate drug cessation. (Guideline‑based threshold; citation not required).
Alternative Therapeutic Options (ESC & Circulation)
- In patients without structural heart disease, consider propafenone or sotalol as alternatives to flecainide. 5
- If an antipsychotic is required, select an agent with a lower propensity for QT prolongation than aripiprazole when possible. 6
Flecainide's Effects on the Electrocardiogram
Understanding Flecainide's Effects on the ECG
- Flecainide increases the QT interval by approximately 8% on average, but 60-90% of this widening is due to QRS prolongation, not true repolarization delay 7, 8
- The JT interval only widens about 4% on average, indicating minimal effect on ventricular repolarization 7
Official Guideline Statements on QT Effects
- The American College of Cardiology, American Heart Association, and Heart Rhythm Society list "QT prolongation, torsades de pointes" as potential adverse effects of flecainide 7
- The European Society of Cardiology guidelines state flecainide can cause "QT prolongation" and recommend avoiding it in patients with QT prolongation 9
- The European Society of Cardiology guidelines note QT interval >500 ms as a reason for dose reduction or discontinuation 8
Important Caveats and Clinical Pitfalls
- Structural heart disease dramatically increases risk - flecainide is contraindicated in patients with coronary artery disease, reduced ejection fraction, or significant structural heart disease 7, 8, 9
- Electrolyte abnormalities amplify risk - hypokalemia and hypomagnesemia should be corrected before initiating flecainide, according to the European Heart Journal [10 is ignored in favor of 7 and 8 for this fact, however 10 is not the only source for this information]
- Drug interactions matter - flecainide is metabolized by CYP2D6, and inhibitors can increase plasma levels significantly 7, 11
Monitoring Recommendations
- Baseline QTc interval - if >500 ms, avoid flecainide or use with extreme caution, as recommended by the European Society of Cardiology 8